REMOVED: A polymorphism in the 5′ untranslated region of ERCC5 determines effectiveness of platinum-based chemotherapeutics

REMOVED: A polymorphism in the 5′ untranslated region of ERCC5 determines effectiveness of platinum-based chemotherapeutics

REMOVED: A polymorphism in the 5′ untranslated region of ERCC5 determines effectiveness of platinum-based chemotherapeutics Joanna Somers1,*,a, Ian G...

36KB Sizes 3 Downloads 26 Views

REMOVED: A polymorphism in the 5′ untranslated region of ERCC5 determines effectiveness of platinum-based chemotherapeutics Joanna Somers1,*,a, Ian G. Cannell2,a, Alexander A. Kondrashov3,a, Laura C. Cobbold1, Lucy Young1, Lindsay Wilson1, Emilie Horvilleur1, John-Paul Kilday4, Keith A. Spriggs3, Richard Grundy4, Martin Bushell1, Anne E. Willis1 1

Medical Research Council Toxicology Unit, Lancaster Rd, Leicester, LE1 9HN, UK 2 David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA 3 School of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, University Park, Nottingham NG72RD, UK 4 Children’s Brain Tumour Research Centre, Queen’s Medical Centre Campus, Nottingham NG72UH, UK This article has been removed: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been removed at the request of the author. This abstract was inadvertently published in the journal when the authors had requested that it should not.

E-mail address: [email protected] (J. Somers). a These authors contributed equally to the work.